Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Barrett's esophagus: current and future management

K K Wang1

  • 1Laser Photodynamics Laboratory, Mayo School of Medicine, Rochester, MN 55905.

Comprehensive Therapy
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved Injury Detection Through Harmonizing Multi-Site Neuroimaging Data after Experimental TBI: A Translational Outcomes Project in NeuroTrauma (TOP-NT) Consortium Study.

bioRxiv : the preprint server for biology·2025
Same author

Improved injury detection through harmonizing multi-site neuroimaging data after experimental TBI: a Translational Outcomes Project in Neurotrauma consortium study.

Frontiers in neurology·2025
Same author

[Effects of neonatal stimulator of interferon genes innate immune signaling pathway of HBsAg-positive mothers on non/hypo-response to hepatitis B vaccine in infants].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2023
Same author

[Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2021
Same author

A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett's esophagus patients after extended follow up; results from Dutch surveillance cohorts.

PloS one·2020
Same author

The Y-chromosome F haplogroup contributes to the development of Barrett's esophagus-associated esophageal adenocarcinoma in a white male population.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2020

Barrett's esophagus, a preneoplastic condition, carries a 40-fold increased risk of neoplasia. Diagnosis involves endoscopy and biopsy, with management focusing on reflux control and surveillance for dysplasia.

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Barrett's esophagus is a preneoplastic condition linked to chronic reflux esophagitis.
  • It presents a significantly increased risk (approx. 40-fold) of neoplasia, with an incidence of 1:200 patient-years.
  • Diagnosis relies on endoscopic visualization and histological confirmation of specialized columnar epithelium (intestinal metaplasia).

Purpose of the Study:

  • To review the diagnostic criteria, risk factors, and current/prospective management strategies for Barrett's esophagus.
  • To highlight the molecular events associated with cancer development in Barrett's esophagus.
  • To discuss the role of surveillance and emerging therapies in managing this condition.

Main Methods:

  • Review of endoscopic and histological diagnostic criteria for Barrett's esophagus.

Related Experiment Videos

  • Analysis of molecular alterations, including tumor suppressor gene (p53) loss and chromosomal abnormalities (5q loss), in Barrett's esophagus progression.
  • Evaluation of current management strategies (reflux control, surveillance biopsies) and prospective therapeutic options.

    • Main Results:

    • Barrett's esophagus is histologically identified by intestinal metaplasia.
    • Neoplastic risk is elevated, particularly with low-grade and high-grade dysplasia.
    • Cancer development is associated with sequential molecular events, including p53 and 5q loss.
    • Current management involves reflux control and surveillance; surgical resection for high-grade dysplasia lacks proven cost-effectiveness.

    Conclusions:

    • Barrett's esophagus requires careful management, including reflux control and vigilant surveillance.
    • Understanding molecular events is crucial for assessing cancer risk.
    • Emerging therapies show promise but require long-term studies to validate their impact on cancer development.